» Articles » PMID: 15734150

Non-enzymatic Hinge Region Fragmentation of Antibodies in Solution

Overview
Publisher Elsevier
Date 2005 Mar 1
PMID 15734150
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Liquid formulations of monoclonal antibodies (MAbs) typically undergo fragmentation near the papain cleavage site in the hinge region, resulting in Fab and Fab+Fc forms. The purpose of this study was to investigate whether this fragmentation is due to proteases. Four closely-related MAbs were exchanged into a pH 5.2 acetate buffer with NaCl and stored at -20 degrees C, 5 degrees C, 30 degrees C, or 40 degrees C for 1 month. Fragmentation generated size-exclusion chromatography (SEC) peak fractions that were analyzed by electrospray mass spectrometry to identify the cleavage sites. The effects of protein inhibitors or host cell proteins on fragmentation were also studied. The extent of fragmentation was equivalent for all four antibodies, occurring in the heavy chain hinge region Ser-Cys-Asp-Lys-Thr-His-Thr sequence. The fragment due to cleavage of the Asp-Lys bond showed two forms that differ by 18 Da. A synthetic peptide with the hinge region sequence terminating with Asp did not show fragmentation or the loss of 18 Da after incubation. Protease inhibitors did not affect rates of cleavage or modify sites of fragmentation. Degradation was not affected by host cell protein content. Fragmentation appears to be a kinetic process that is not caused by low levels of host cell proteases.

Citing Articles

Considerations on the stability of IgG antibody in clinical specimens.

Yen L, Henao-Diaz A, Zimmerman J, Gimenez-Lirola L J Vet Diagn Invest. 2024; 37(1):13-26.

PMID: 39673476 PMC: 11645686. DOI: 10.1177/10406387241296848.


Developability considerations for bispecific and multispecific antibodies.

Amash A, Volkers G, Farber P, Griffin D, Davison K, Goodman A MAbs. 2024; 16(1):2394229.

PMID: 39189686 PMC: 11352713. DOI: 10.1080/19420862.2024.2394229.


Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control.

Yang F, Zhang J, Buettner A, Vosika E, Sadek M, Hao Z MAbs. 2023; 15(1):2197668.

PMID: 37057828 PMC: 10114992. DOI: 10.1080/19420862.2023.2197668.


Characterization of bispecific antigen-binding biotherapeutic fragmentation sites using microfluidic capillary electrophoresis coupled to mass spectrometry (mCZE-MS).

Shah A, Desai R, Cui W, Harrahy J, Ivanov A Analyst. 2023; 148(3):665-674.

PMID: 36625279 PMC: 9979615. DOI: 10.1039/d2an01724e.


Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.

Dippel A, Gallegos A, Aleti V, Barnes A, Chen X, Christian E MAbs. 2022; 15(1):2152526.

PMID: 36476037 PMC: 9733695. DOI: 10.1080/19420862.2022.2152526.